Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy.

ABSTRACT: Glioblastoma (GBM) is the most prevalent, aggressive primary brain tumour with a dismal prognosis. Treatment at diagnosis has limited efficacy and there is no standardised treatment at recurrence. New, personalised treatment options are under investigation, although challenges persist for heterogenous tumours such as GBM. Gene editing technologies are a game changer, enabling design of novel molecular-immunological treatments to be used in combination with chemoradiation, to achieve long lasting survival benefits for patients. Here, we review the literature on how cutting-edge molecular gene editing technologies can be applied to known and emerging tumour-associated antigens to enhance chimeric antigen receptor T and NK cell therapies for GBM. A tight balance of limiting neurotoxicity, avo

SUBMITTER: Arnesen VS 

PROVIDER: S-EPMC8507952 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature